AsiaIntervention最新文献_第4页

A ruptured coronary artery aneurysm treated by covered stent implantation. 通过覆盖支架植入术治疗冠状动脉动脉瘤破裂。

AsiaIntervention Pub Date : 2024-07-26 eCollection Date: 2024-07-01 DOI: 10.4244/AIJ-D-23-00039

Mao Matsuyama Terui, Takashi Ashikaga, Toshihiro Nozato, Ryoichi Miyazaki

引用次数: 0

Current status of percutaneous coronary interventions in diabetics with multivessel disease - is it time to challenge FREEDOM? 多血管疾病糖尿病患者经皮冠状动脉介入治疗的现状--现在是挑战 FREEDOM 的时候了吗？

AsiaIntervention Pub Date : 2024-07-26 eCollection Date: 2024-07-01 DOI: 10.4244/AIJ-D-24-00016

Upendra Kaul, Krishnankutty Sudhir, Sripal Bangalore

{"title":"Current status of percutaneous coronary interventions in diabetics with multivessel disease - is it time to challenge FREEDOM?","authors":"Upendra Kaul, Krishnankutty Sudhir, Sripal Bangalore","doi":"10.4244/AIJ-D-24-00016","DOIUrl":"10.4244/AIJ-D-24-00016","url":null,"abstract":"Diabetes mellitus (DM) and coronary artery disease (CAD) are the leading causes of death in the world. Over the last two decades, clinical trials have indicated that DM patients with CAD have poorer cardiac outcomes than non-diabetic patients with CAD. The pivotal findings of the FREEDOM trial greatly impacted the way clinicians approached revascularisation in diabetic patients with multivessel disease (MVD). However, since the publication of the FREEDOM trial, much has changed both in percutaneous coronary intervention (PCI) technology, as well as in the management of diabetes. This review provides insights into advancements in stent technology, enhanced patient management strategies, improved clinical outcomes with newer hypoglycaemic agents, current approaches to antiplatelet therapy, and advances in lipid management in diabetic patients. The influence of patient-specific factors such as comorbidities and anatomical complexities on treatment decisions in diabetic patients with MVD is also discussed. The ongoing TUXEDO-2 India trial was designed to primarily compare the clinical outcomes of PCI with the new-generation ultrathin-strut Supraflex Cruz stent, compared to the second-generation XIENCE stent in the setting of contemporary optimal medical therapy in Indian diabetic patients with MVD. The secondary objective of this study is to compare clinical outcomes in the combined group from both study arms against a performance goal derived from the coronary artery bypass grafting (CABG) arm of the FREEDOM trial (historical cohort). The tertiary objective is to compare the efficacy and safety of ticagrelor versus prasugrel in diabetic patients with MVD. In view of recent advances in PCI and medical therapy since the FREEDOM trial, now is an appropriate time to revisit the results of CABG versus PCI in diabetic patients with MVD.","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":"10 2","pages":"102-109"},"PeriodicalIF":0.0,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11261656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141790167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Angiographic patterns after drug-coated balloon angioplasty for de novo coronary lesions. 药物涂层球囊血管成形术治疗新发冠状动脉病变后的血管造影模式。

AsiaIntervention Pub Date : 2024-07-26 eCollection Date: 2024-07-01 DOI: 10.4244/AIJ-D-23-00064

Naohiro Funayama, Keigo Kayanuma, Daisuke Sunaga, Makoto Furugen

{"title":"Angiographic patterns after drug-coated balloon angioplasty for de novo coronary lesions.","authors":"Naohiro Funayama, Keigo Kayanuma, Daisuke Sunaga, Makoto Furugen","doi":"10.4244/AIJ-D-23-00064","DOIUrl":"10.4244/AIJ-D-23-00064","url":null,"abstract":"Background: Drug-coated balloon (DCB) angioplasty has emerged as an effective treatment option for de novo coronary artery lesions; however, the chronic-phase angiographic patterns after DCB angioplasty for de novo lesions have not yet been described.Aims: The aim of the present study was to evaluate chronic-phase angiographic classification after DCB angioplasty.Methods: This was a single-centre, retrospective, observational study. From June 2016 to August 2022, 708 lesions (670 patients) underwent DCB angioplasty for de novo coronary lesions. Successful DCB angioplasty was defined as a non-flow-limiting dissection, with residual stenosis ≤30% and absence of a bailout stent. A total of 337 lesions (318 patients) were enrolled in this study.Results: Of the 337 lesions analysed, 91.1% (n=307) were in the non-restenosis group, and 8.9% (n=30) were in the restenosis group. The non-restenosis group was classified into non-restenosis (45.1%; n=152) and lumen enlargement (46.0%; n=155). The restenosis group was classified into focal restenosis (5.0%; n=17), diffuse restenosis (3.6%; n=12), and occlusive restenosis (0.3%; n=1). There were no aneurysms, and plaque cavities were often observed (8.0%). During the chronic phase, residual dissection was seen in only one case (0.3%).Conclusions: This report demonstrates for the first time the angiographic classification after DCB angioplasty for de novo coronary lesions. Restenosis patterns were seen in 8.9% of lesions, and half of the restenosis patterns presented a focal restenosis pattern. Late lumen enlargement was observed in 46% of the treated lesions.","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":"10 2","pages":"119-125"},"PeriodicalIF":0.0,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11261657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141790164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complex PCI of the RCA using an anchoring balloon in a circumflex artery. 在环状动脉中使用锚定球囊对 RCA 进行复杂 PCI。

AsiaIntervention Pub Date : 2024-07-26 eCollection Date: 2024-07-01 DOI: 10.4244/AIJ-D-23-00070

Heberto Aquino Bruno, Marco A Alcantara-Meléndez, Juan F García-García, Carlos Roque-Palacios, Martin Cedillo-Urbina, Kevin R Hernandez-Flores

引用次数: 0

Drug-coated balloon angioplasty for coronary de novo lesions - hype or hope? 药物涂层球囊血管成形术治疗冠状动脉新发病变--炒作还是希望？

AsiaIntervention Pub Date : 2024-07-26 eCollection Date: 2024-07-01 DOI: 10.4244/AIJ-E-24-00002

Bruno Scheller

引用次数: 0

Transcatheter aortic valve replacement in China - a review of the available evidence. 中国经导管主动脉瓣置换术--现有证据综述。

AsiaIntervention Pub Date : 2024-07-26 eCollection Date: 2024-07-01 DOI: 10.4244/AIJ-D-23-00049

Lai Wei, Bin Wang, Ye Yang, Lili Dong, Xiang Chen, Peter Bramlage, Yan Wang

{"title":"Transcatheter aortic valve replacement in China - a review of the available evidence.","authors":"Lai Wei, Bin Wang, Ye Yang, Lili Dong, Xiang Chen, Peter Bramlage, Yan Wang","doi":"10.4244/AIJ-D-23-00049","DOIUrl":"10.4244/AIJ-D-23-00049","url":null,"abstract":"This paper discusses aortic stenosis (AS) in China, emphasising the role of transcatheter aortic valve replacement (TAVR) in treating AS in an ageing population. AS characteristics, its treatment and the clinical outcomes of transfemoral TAVR in Chinese patients are described via a systematic review. AS affects >1% of the Chinese population aged ≥65 years, with degenerative AS predominating over rheumatic AS among this age group. Chinese patients often have high aortic valve (AV) calcification with bicuspid AV morphology. In 2021, 38,000 surgical aortic valve replacements (SAVR) were reported in China, while the number of TAVR increased from 293 in 2017 to 7,357 in 2021. There are four self-expanding valves and one balloon-expandable SAPIEN 3 valve available in China. Among them, the Venus A-Valve is the most studied and widely used, whereas limited data are available for VitaFlow, TaurusOne, and SAPIEN 3. Notably, 10.0-16.5% of Venus A-Valve recipients and 0.2% of SAPIEN 3 recipients required multiple valve implantations. The rates of 30-day paravalvular leakage were 0-11.7%/0% for Venus A-Valve, 2.0%/0% for VitaFlow, and 0%/0% for SAPIEN 3, for moderate and severe leakage, respectively. Thirty-day all-cause mortality rates were 3.7-10.0% for Venus A-Valve, 0.9% for VitaFlow, and 0-3.2% for SAPIEN 3. One-year all-cause mortality rates were 5.9-13.6% for Venus A-Valve, 0-4.5% for VitaFlow, 6.7% for TaurusOne, and 6.2% for SAPIEN 3. The Venus A-Valve indicated lower 30-day permanent pacemaker implantation (PPI) rates (7.4-20.5%) than VitaFlow and TaurusOne. Outcomes for patients with bicuspid or tricuspid aortic valves were similar. AS is rising among the elderly Chinese population; SAVR is common, and TAVR is increasing. Limited device comparisons exist, but the Venus A-Valve seems to have lower PPI rates, and SAPIEN 3 has low 30-day mortality in China.","PeriodicalId":72310,"journal":{"name":"AsiaIntervention","volume":"10 2","pages":"110-118"},"PeriodicalIF":0.0,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11261658/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141790172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stent infections: elephant in the room. 支架感染：房间里的大象。

AsiaIntervention Pub Date : 2024-07-26 eCollection Date: 2024-07-01 DOI: 10.4244/AIJ-E-24-00003

Anil Dhall, Kirti Punamiya

引用次数: 0

A curious case of type IV dual LAD presenting with ST-elevation myocardial infarction. 一例以 ST 段抬高型心肌梗死为特征的 IV 型双 LAD 病例。

AsiaIntervention Pub Date : 2024-02-29 eCollection Date: 2024-02-01 DOI: 10.4244/AIJ-D-23-00046

Sushant Kharel, Kunjang Sherpa, Sanjay Singh Kc, Dipanker Prajapati, Rikesh Tamrakar

引用次数: 0

Artificial intelligence in medical writing. 医学写作中的人工智能。

AsiaIntervention Pub Date : 2024-02-29 eCollection Date: 2024-02-01 DOI: 10.4244/AIJ-E-23-00005

James Howard, Hoi Ching Cheung

引用次数: 0

Conduction disturbance following valve-in-valve implantation in a 19 mm surgical valve: impact on implantation depth in an ex vivo experiment. 在 19 毫米手术瓣膜中植入瓣膜后的传导干扰：体内外实验中植入深度的影响。

AsiaIntervention Pub Date : 2024-02-29 eCollection Date: 2024-02-01 DOI: 10.4244/AIJ-D-23-00028

Tomoaki Kobayashi, Kensuke Takagi, Atsushi Okada, Teruo Noguchi

引用次数: 0